Welcome to our dedicated page for Coherus Oncology SEC filings (Ticker: CHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Coherus Oncology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Coherus Oncology's regulatory disclosures and financial reporting.
Coherus Oncology, Inc. filed a current report to share that it is furnishing preliminary, unaudited financial information for the quarter and fiscal year ended December 31, 2025. The company will present preliminary net revenues and levels of cash, cash equivalents and investments at the 43rd Annual J.P. Morgan Healthcare Conference, with this data included in a slide deck furnished as Exhibit 99.1.
Coherus stresses that its financial closing procedures for this period are not yet complete, so final results may differ materially from the preliminary figures, and its independent registered public accounting firm has not reviewed or audited these results. The presentation also contains forward-looking statements, including projected revenue growth of LOQTORZI, which the company notes are subject to significant risks such as financing needs, market acceptance of its products and litigation risks.
Coherus Oncology, Inc. filed a shelf registration statement on Form S-3 to offer and sell up to $150.0 million of mixed securities, including common stock, preferred stock, debt securities, warrants, and units, from time to time in one or more offerings. Each sale will be detailed in a prospectus supplement describing specific terms and pricing.
The filing replaces a prior registration and, under Rule 415, permits offerings via underwriters, dealers, agents, or direct sales. The company’s common stock trades on Nasdaq as CHRS; the last reported sale price was $1.36 per share on November 12, 2025. Use of proceeds will be described in the applicable prospectus supplement.
Coherus Oncology filed a Form S-8 registering 1,500,000 additional shares of common stock for its 2014 Employee Stock Purchase Plan, as approved by stockholders on June 11, 2025.
The filing adds capacity for employee share purchases under the ESPP. It includes customary exhibits, including a legal opinion from Latham & Watkins LLP, and notes Coherus is an accelerated filer and a smaller reporting company.
Coherus Oncology (CHRS) recast prior financials to reflect discontinued operations after divesting its UDENYCA franchise. The company completed the UDENYCA sale to Intas on April 11, 2025 for upfront, all‑cash consideration of $483.4 million, which included $118.4 million for product inventory. Coherus is also eligible for two additional earn‑out payments of $37.5 million each.
Exhibit 99.1 updates selected sections of the 2024 Form 10‑K to present the biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI) as discontinued operations for the fiscal years ended December 31, 2024 and 2023. The recast information is intended for incorporation by reference into a Form S‑3 expected to be filed on November 13, 2025. The filing limits changes to those necessary for the discontinued operations presentation, maintaining the nature and character of the original disclosures.
Coherus Oncology (CHRS) reported Q3 2025 results. Continuing operations net revenue was $11,571, driven by LOQTORZI revenue of $11,169. Loss from continuing operations was $(44,517). Discontinued operations contributed net income of $8,986, resulting in a quarterly net loss of $(35,531).
The company closed the divestiture of the UDENYCA franchise on April 11, 2025 for upfront cash of $483.4 million, recognizing a net gain of $338.7 million. Proceeds were used to redeem substantially all 2026 convertible notes and to buy out UDENYCA royalty rights for $47.7 million.
As of September 30, 2025, cash and cash equivalents were $103,352 and investments in marketable securities were $88,311. Total assets were $516,519, total liabilities $428,745, and stockholders’ equity was $87,774. Shares outstanding were 116,236,018 at quarter end.
Coherus Oncology, Inc. (CHRS) reported that it furnished, not filed, a press release announcing financial results for the fiscal quarter ended September 30, 2025. The company disclosed this under Item 2.02 and attached the full text as Exhibit 99.1.
The submission clarifies that the information provided under Item 2.02 and Exhibit 99.1 is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference unless specifically stated. The filing also includes the Cover Page Inline XBRL as Exhibit 104.
Coherus Oncology, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing. The company previously received a Nasdaq deficiency notice on June 30, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days, giving it until December 29, 2025 to cure the issue.
On September 5, 2025, Nasdaq informed Coherus that the closing price of its common stock had been $1.00 or greater for the requisite period, restoring compliance with Listing Rule 5550(a)(2). Coherus is now in full compliance with all continued listing standards of the Nasdaq Global Market, removing the immediate risk associated with the prior deficiency notice.